Pseudomonas aeruginosa genotypes acquired by children with cystic fibrosis by age 5-years

Journal of Cystic Fibrosis

Volumn 14, Issue 3, 2015, Pages 361-369

  Kidd, Timothy J ^b   Ramsay, Kay A ^b   Vidmar, Suzanna ^g,h   Carlin, John B ^g,h   Bell, Scott C ^b,q   Wainwright, Claire E ^a,b,d   Grimwood, Keith ^a,b,c   Francis, Paul W ^d   Dakin, Carolyn ^e   Cheney, Joyce ^a,b   George, Narelle ^f   Robertson, Colin F ⁱ   Moodie, Marj ^j   Carzino, Rosemary ⁱ   Carter, Robert ^j   Armstrong, David S ^k   Cooper, Peter J ^l   McKay, Karen ^l   Martin, A James ^m   Whitehead, Bruce ^h   Hunter, John ⁿ   Byrnes, Catherine A ^o   Tiddens, Harm A ^p   Graniel, Karla ^h   Gerbrands, Krista ^h   Mott, Lauren ^h   more..

^a Queensland Children's Medical Research Institute   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c GRIFFITH UNIVERSITY   (Australia)

^d ROYAL CHILDREN'S HOSPITAL   (Australia)

^e MATER CHILDREN S HOSPITAL   (Australia)

^f Pathology Queensland   (Australia)

^g MURDOCH CHILDREN'S RESEARCH INSTITUTE   (Australia)

^h UNIVERSITY OF MELBOURNE   (Australia)

ⁱ ROYAL CHILDREN'S HOSPITAL   (Australia)

^j DEAKIN UNIVERSITY   (Australia)

^k MONASH MEDICAL CENTRE   (Australia)

^l CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^m WOMEN S AND CHILDREN S HOSPITAL   (Australia)

ⁿ ACT Health   (Australia)

^o STARSHIP CHILDREN S HOSPITAL   (New Zealand)

^p ERASMUS MEDICAL CENTER   (Netherlands)

^q THE PRINCE CHARLES HOSPITAL   (Australia)

more..

Author keywords

Cystic fibrosis; Eradication; Genotyping; Infection; Pseudomonas aeruginosa

Indexed keywords

CEFTAZIDIME; CIPROFLOXACIN; PRESCRIPTION DRUG; TIMENTIN; TOBRAMYCIN; ANTIINFECTIVE AGENT; BACTERIAL DNA;

ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL STRAIN; BACTERIUM CULTURE; BACTERIUM ISOLATE; CHILD; CHRONOTHERAPY; CYSTIC FIBROSIS; ERADICATION THERAPY; FEMALE; GENOTYPE; HUMAN; INTERVENTION STUDY; LONGITUDINAL STUDY; LOWER RESPIRATORY TRACT; LUNG LAVAGE; MAJOR CLINICAL STUDY; MALE; NONHUMAN; OROPHARYNX; PRESCHOOL CHILD; PRESCRIPTION; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SECONDARY ANALYSIS; UPPER RESPIRATORY TRACT; BRONCHOALVEOLAR LAVAGE FLUID; CLINICAL TRIAL; COMPLICATION; CONTROLLED STUDY; FOLLOW UP; GENETICS; INFANT; ISOLATION AND PURIFICATION; MICROBIOLOGY; MULTICENTER STUDY; PSEUDOMONAS INFECTIONS; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY;

ANTI-BACTERIAL AGENTS; BRONCHOALVEOLAR LAVAGE FLUID; CHILD, PRESCHOOL; CYSTIC FIBROSIS; DNA, BACTERIAL; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HUMANS; INFANT; MALE; OROPHARYNX; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RETROSPECTIVE STUDIES;

EID: 84937516045     PISSN: 15691993     EISSN: 18735010     Source Type: Journal    
DOI: 10.1016/j.jcf.2014.12.007     Document Type: Article

References (37)

1. Burns J.L., Gibson R.L., McNamara S., Yim D., Emerson J., Rosenfeld M., et al. Longitudinal assessment of Pseudomonas aeruginosa in young children with cystic fibrosis. J Infect Dis 2001, 183(3):444-452.
2. Macdonald D., Cuthbertson L., Doherty C., Campana S., Ravenni N., Taccetti G., et al. Early Pseudomonas aeruginosa infection in individuals with cystic fibrosis: is susceptibility testing justified?. J Antimicrob Chemother 2010, 65(11):2373-2375.
3. Yang L., Jelsbak L., Molin S. Microbial ecology and adaptation in cystic fibrosis airways. Environ Microbiol 2011, 13(7):1682-1689.
4. Mayer-Hamblett N., Rosenfeld M., Gibson R.L., Ramsey B.W., Kulasekara H.D., Retsch-Bogart G.Z., et al. Pseudomonas aeruginosa in vitro phenotypes distinguish cystic fibrosis infection stages and outcomes. Am J Respir Crit Care Med 2014, 190(3):289-297.
5. Nixon G.M., Armstrong D.S., Carzino R., Carlin J.B., Olinsky A., Robertson C.F., et al. Clinical outcome after early Pseudomonas aeruginosa infection in cystic fibrosis. J Pediatr 2001, 138(5):699-704.
6. Emerson J., Rosenfeld M., McNamara S., Ramsey B., Gibson R.L. Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr Pulmonol 2002, 34(2):91-100.
7. Schelstraete P., Haerynck F., Van daele S., Deseyne S., De Baets F. Eradication therapy for Pseudomonas aeruginosa colonization episodes in cystic fibrosis patients not chronically colonized by P. aeruginosa. J Cyst Fibros 2013, 12(1):1-8.
8. Kidd T.J., Ramsay K.A., Hu H., Marks G.B., Wainwright C.E., Bye P.T., et al. Shared Pseudomonas aeruginosa genotypes are common in Australian cystic fibrosis centres. Eur Respir J 2013, 41(5):1091-1100.
9. Gibson R.L., Emerson J., Mayer-Hamblett N., Burns J.L., McNamara S., Accurso F.J., et al. Duration of treatment effect after tobramycin solution for inhalation in young children with cystic fibrosis. Pediatr Pulmonol 2007, 42(7):610-623.
10. Munck A., Bonacorsi S., Mariani-Kurkdjian P., Lebourgeois M., Gerardin M., Brahimi N., et al. Genotypic characterization of Pseudomonas aeruginosa strains recovered from patients with cystic fibrosis after initial and subsequent colonization. Pediatr Pulmonol 2001, 32(4):288-292.
11. Ratjen F., Munck A., Kho P., Angyalosi G., Group E.S. Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: the ELITE trial. Thorax 2010, 65(4):286-291.
12. Schelstraete P., Deschaght P., Van Simaey L., Van Daele S., Haerynck F., Vaneechoutte M., et al. Genotype based evaluation of Pseudomonas aeruginosa eradication treatment success in cystic fibrosis patients. J Cyst Fibros 2010, 9(2):99-103.
13. Taccetti G., Bianchini E., Cariani L., Buzzetti R., Costantini D., Trevisan F., et al. Early antibiotic treatment for Pseudomonas aeruginosa eradication in patients with cystic fibrosis: a randomised multicentre study comparing two different protocols. Thorax 2012, 67(10):853-859.
14. Taccetti G., Campana S., Festini F., Mascherini M., Doring G. Early eradication therapy against Pseudomonas aeruginosa in cystic fibrosis patients. Eur Respir J 2005, 26(3):458-461.
15. Jung A., Kleinau I., Schonian G., Bauernfeind A., Chen C., Griese M., et al. Sequential genotyping of Pseudomonas aeruginosa from upper and lower airways of cystic fibrosis patients. Eur Respir J 2002, 20(6):1457-1463.
16. Muhlebach M.S., Miller M.B., Moore C., Wedd J.P., Drake A.F., Leigh M.W. Are lower airway or throat cultures predictive of sinus bacteriology in cystic fibrosis?. Pediatr Pulmonol 2006, 41(5):445-451.
17. Armstrong D.S., Grimwood K., Carlin J.B., Carzino R., Olinsky A., Phelan P.D. Bronchoalveolar lavage or oropharyngeal cultures to identify lower respiratory pathogens in infants with cystic fibrosis. Pediatr Pulmonol 1996, 21(5):267-275.
18. Wainwright C.E., Vidmar S., Armstrong D.S., Byrnes C.A., Carlin J.B., Cheney J., et al. Effect of bronchoalveolar lavage-directed therapy on Pseudomonas aeruginosa infection and structural lung injury in children with cystic fibrosis: a randomized trial. JAMA 2011, 306(2):163-171.
19. Kidd T.J., Ritchie S.R., Ramsay K.A., Grimwood K., Bell S.C., Rainey P.B. Pseudomonas aeruginosa exhibits frequent recombination, but only a limited association between genotype and ecological Setting. PLoS One 2012, 7(9):e44199.
20. Fibrosis Australia Cystic Infection control guidelines for cystic fibrosis patients and carers 2007, Cystic Fibrosis Australia, Sydney.
21. Byrnes C.A., Vidmar S., Cheney J.L., Carlin J.B., Armstrong D.S., Cooper P.J., et al. Prospective evaluation of respiratory exacerbations in children with cystic fibrosis from newborn screening to 5years of age. Thorax 2013, 68(7):643-651.
22. Rosenfeld M., Emerson J., Accurso F., Armstrong D., Castile R., Grimwood K., et al. Diagnostic accuracy of oropharyngeal cultures in infants and young children with cystic fibrosis. Pediatr Pulmonol 1999, 28(5):321-328.
23. Wainwright C.E., Grimwood K., Carlin J.B., Vidmar S., Cooper P.J., Francis P.W., et al. Safety of bronchoalveolar lavage in young children with cystic fibrosis. Pediatr Pulmonol 2008, 43(10):965-972.
24. Kidd T.J., Grimwood K., Ramsay K.A., Rainey P.B., Bell S.C. Comparison of three molecular techniques for typing Pseudomonas aeruginosa isolates in sputum samples from patients with cystic fibrosis. J Clin Microbiol 2011, 49(1):263-268.
25. Armstrong D.S., Nixon G.M., Carzino R., Bigham A., Carlin J.B., Robins-Browne R.M., et al. Detection of a widespread clone of Pseudomonas aeruginosa in a pediatric cystic fibrosis clinic. Am J Respir Crit Care Med 2002, 166(7):983-987.
26. O'Carroll M.R., Syrmis M.W., Wainwright C.E., Greer R.M., Mitchell P., Coulter C., et al. Clonal strains of Pseudomonas aeruginosa in paediatric and adult cystic fibrosis units. Eur Respir J 2004, 24(1):101-106.
27. Ranganathan S.C., Skoric B., Ramsay K.A., Carzino R., Gibson A.M., Hart E., et al. Geographical differences in first acquisition of Pseudomonas aeruginosa in cystic fibrosis. Ann Am Thorac Soc 2013, 10(2):108-114.
28. Moodie M., Lal A., Vidmar S., Armstrong D.S., Byrnes C.A., Carlin J.B., et al. Costs of bronchoalveolar lavage-directed therapy in the first 5years of life for children with cystic fibrosis. J Pediatr 2014, 165(3):564-569.
29. Aanaes K. Bacterial sinusitis can be a focus for initial lung colonisation and chronic lung infection in patients with cystic fibrosis. J Cyst Fibros 2013, 12(Suppl. 2):S1-S20.
30. Hansen S.K., Rau M.H., Johansen H.K., Ciofu O., Jelsbak L., Yang L., et al. Evolution and diversification of Pseudomonas aeruginosa in the paranasal sinuses of cystic fibrosis children have implications for chronic lung infection. ISME J 2012, 6(1):31-45.
31. Lavin J., Bhushan B., Schroeder J.W. Correlation between respiratory cultures and sinus cultures in children with cystic fibrosis. Int J Pediatr Otorhinolaryngol 2013, 77(5):686-689.
32. Manos J., Hu H., Rose B.R., Wainwright C.E., Zablotska I.B., Cheney J., et al. Virulence factor expression patterns in Pseudomonas aeruginosa strains from infants with cystic fibrosis. Eur J Clin Microbiol Infect Dis 2013, 32(12):1583-1592.
33. Moore R., Kyd J.M., Carzino R., Armstrong D., Grimwood K., Otczyk D.C., et al. Mucosal and systemic antibody responses to potential Pseudomonas aeruginosa vaccine protein antigens in young children with cystic fibrosis following colonization and infection. Hum Vaccin Immunother 2013, 9(3):506-514.
34. Daines C., VanDeVanter D., Khan U., Emerson J., Heltshe S., McNamara S., et al. Serology as a diagnostic tool for predicting initial Pseudomonas aeruginosa acquisition in children with cystic fibrosis. J Cyst Fibros 2014, 13:542-549.
35. Douglas T.A., Brennan S., Berry L., Winfield K., Wainwright C.E., Grimwood K., et al. Value of serology in predicting Pseudomonas aeruginosa infection in young children with cystic fibrosis. Thorax 2010, 65(11):985-990.
36. Mauch R.M., Levy C.E. Serum antibodies to Pseudomonas aeruginosa in cystic fibrosis as a diagnostic tool: a systematic review. J Cyst Fibros 2014, 13:499-507.
37. Whiteson K.L., Bailey B., Bergkessel M., Conrad D., Delhaes L., Felts B., et al. The upper respiratory tract as a microbial source for pulmonary infections in cystic fibrosis. Parallels from island biogeography. Am J Respir Crit Care Med 2014, 189(11):1309-1315.